Pacira BioSciences Under Shareholder Pressure for Governance Reforms and Executive Compensation Review

Corporate Governance at Pacira BioSciences Faces Scrutiny Amid Shareholder Activism

In recent developments, DOMA Perpetual Capital Management LLC, a significant stakeholder in Pacira BioSciences, Inc. with a 6.83% ownership stake, calls for a formal sales process and a review of the company's executive compensation practices. The Miami-based asset management firm expresses concerns over what it perceives as excessive and unjustified spending by the current executive team. DOMA's public statement, released on December 30, 2025, underscores a growing movement among shareholders advocating for improved corporate governance within Pacira. The firm intends to nominate three independent director candidates for the upcoming 2026 annual stockholders' meeting, aiming to enhance fiduciary oversight and accountability within the board.

DOMA's push for change reflects broader trends in the biopharmaceutical sector, where shareholders increasingly demand greater transparency and responsible management of resources. The firm emphasizes the need for directors who can bring fresh perspectives and oversight to ensure that executive compensation aligns with performance metrics and shareholder interests. By filing a preliminary proxy statement and introducing a white proxy card with the Securities and Exchange Commission (SEC), DOMA aims to facilitate a more participatory environment for shareholders during the election process. This advocacy for reform is indicative of a larger sentiment among investors seeking to hold companies accountable for their governance practices.

The outcome of DOMA's initiatives may significantly impact Pacira's strategic direction and operational efficiency. If successful, the proposed changes could lead to a reassessment of current spending practices and a more rigorous evaluation of executive performance. This scrutiny may also prompt other shareholders to re-evaluate their positions and engage more actively in corporate governance discussions. The situation highlights the critical nature of board effectiveness in fostering a culture of accountability and sustainable growth in the biopharmaceutical industry.

In addition to the governance concerns, the upcoming proxy materials, which will be available for free on the SEC's website, are expected to provide shareholders with crucial insights into DOMA's proposed candidates and their vision for Pacira's future. The firm encourages all stakeholders to review these materials carefully, as they will contain essential information that can influence the company's trajectory. As the landscape of corporate governance evolves, Pacira BioSciences stands at a crossroads, with its board's decisions poised to shape its operational success and reputation in the biopharmaceutical market.